Literature DB >> 16988302

The PRIMA study: presentation ischaemia-modified albumin in the emergency department.

L Keating1, J R Benger, R Beetham, S Bateman, S Veysey, J Kendall, R Pullinger.   

Abstract

OBJECTIVES: To investigate the diagnostic accuracy of presentation ischaemia-modified albumin (IMA), in addition to cardiac troponin I (TnI), as a strategy to rapidly ascribe low risk to patients with chest pain attending an emergency department, and to determine whether IMA has the potential to reduce transit time in emergency departments.
METHODS: A prospective observational study was carried out in two emergency departments (belonging to the John Radcliffe Hospital, Oxford, UK; and the Frenchay Hospital, Bristol, UK) of similar size. Consecutive adult patients presenting with features of possible ischaemic cardiac chest pain and a normal electrocardiogram were eligible. The index test (measurement of IMA and TnI at presentation) and reference standard (delayed TnI measurement, taken at least 8 h after pain onset) were applied to all recruited patients. All clinicians were blinded to the results of the index test. Assays were carried out in a single laboratory using standard techniques.
RESULTS: 399 patients were recruited; 277 patients had a result for both the index test and reference standard. The sensitivity was 97.6% (95% confidence interval (CI) 87.4 to 99.9), negative predictive value 97% (95% CI 84.2 to 99.9) and specificity 13.6% (95% CI 9.5 to 18.7). Sensitivity analysis showed similar findings in three alternative scenarios. Receiver operating characteristic analysis indicated that a different "cut-off" value for IMA would not improve the properties of the test. The median potential time saved (n = 268) was 6 h and 10 min.
CONCLUSION: The diagnostic accuracy of presentation IMA in this study does not support its use as an effective risk stratification tool for patients with chest pain in the emergency department. The sensitivity is insufficiently high, with a small number of false negatives undermining the safety of the test. Frequent false positives produce a low specificity that limits the practical value of the test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988302      PMCID: PMC2579595          DOI: 10.1136/emj.2006.036269

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  15 in total

1.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

2.  Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.

Authors:  David A Morrow; Nader Rifai; Marc S Sabatine; Shake Ayanian; Sabina A Murphy; James A de Lemos; Eugene Braunwald; Christopher P Cannon
Journal:  Clin Chem       Date:  2003-08       Impact factor: 8.327

Review 3.  Markers to define ischemia: are they ready for prime time use in patients with acute coronary syndromes?

Authors:  Jesse Adams
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

4.  Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I.

Authors:  D Bar-Or; J V Winkler; K Vanbenthuysen; L Harris; E Lau; F W Hetzel
Journal:  Am Heart J       Date:  2001-06       Impact factor: 4.749

Review 5.  Chest pain centers: diagnosis of acute coronary syndromes.

Authors:  A B Storrow; W B Gibler
Journal:  Ann Emerg Med       Date:  2000-05       Impact factor: 5.721

6.  Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes.

Authors:  M K Sinha; D Roy; D C Gaze; P O Collinson; J C Kaski
Journal:  Emerg Med J       Date:  2004-01       Impact factor: 2.740

7.  Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T.

Authors:  Debashis Roy; Juan Quiles; Guillermo Aldama; Manas Sinha; Pablo Avanzas; Ramón Arroyo-Espliguero; David Gaze; Paul Collinson; Juan Carlos Kaski
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

8.  Utility of admission cardiac troponin and "Ischemia Modified Albumin" measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department.

Authors:  P O Collinson; D C Gaze; K Bainbridge; F Morris; B Morris; A Price; S Goodacre
Journal:  Emerg Med J       Date:  2006-04       Impact factor: 2.740

9.  Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction.

Authors:  A H Wu; D L Morris; D R Fletcher; F S Apple; R H Christenson; P C Painter
Journal:  Cardiovasc Toxicol       Date:  2001       Impact factor: 3.231

10.  Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction.

Authors:  Nadhipuram V Bhagavan; Ernest M Lai; Patricia A Rios; Jinsheng Yang; Anna M Ortega-Lopez; Hiroko Shinoda; Stacey A A Honda; Carlos N Rios; Cheryl E Sugiyama; Chung-Eun Ha
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

View more
  8 in total

1.  Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes.

Authors:  C Bhakthavatsala Reddy; Cijo Cyriac; Hrishikesh B Desle
Journal:  Indian Heart J       Date:  2014-12-22

Review 2.  Diagnostic Accuracy of Ischemia-Modified Albumin for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Hyungoo Shin; Jae-Guk Kim; Bo-Hyoung Jang; Tae-Ho Lim; Wonhee Kim; Youngsuk Cho; Kyu-Sun Choi; Min-Kyun Na; Chiwon Ahn; Juncheol Lee
Journal:  Medicina (Kaunas)       Date:  2022-04-28       Impact factor: 2.948

3.  Serum and saliva levels of ischemia-modified albumin in patients with acute myocardial infarction.

Authors:  Aysun Toker; Alpay Aribas; F Hümeyra Yerlikaya; Erkan Tasyurek; Kürşat Akbuğa
Journal:  J Clin Lab Anal       Date:  2013-02-11       Impact factor: 2.352

4.  Derivation and validation of a sensitive IMA cutpoint to predict cardiac events in patients with chest pain.

Authors:  A F Manini; J Ilgen; V E Noble; F Bamberg; W Koenig; J S Bohan; U Hoffmann
Journal:  Emerg Med J       Date:  2009-11       Impact factor: 2.740

5.  The Association between Diabetic Retinopathy and Levels of Ischemia-Modified Albumin, Total Thiol, Total Antioxidant Capacity, and Total Oxidative Stress in Serum and Aqueous Humor.

Authors:  Kadir Kirboga; Ayse V Ozec; Mustafa Kosker; Ayhan Dursun; Mustafa I Toker; Huseyin Aydin; Haydar Erdogan; Aysen Topalkara; Mustafa K Arici
Journal:  J Ophthalmol       Date:  2014-12-16       Impact factor: 1.909

6.  The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism.

Authors:  Suleyman Turedi; Abdulkadir Gunduz; Ahmet Mentese; Murat Topbas; Suleyman C Karahan; Selman Yeniocak; Ibrahim Turan; Oguz Eroglu; Utku Ucar; Yunus Karaca; Suha Turkmen; Robert M Russell
Journal:  Respir Res       Date:  2008-05-30

7.  Diagnostic Utility of Neuregulin for Acute Coronary Syndrome.

Authors:  Maame Yaa A B Yiadom; Jeremy Greenberg; Holly M Smith; Douglas B Sawyer; Dandan Liu; Jahred Carlise; Laura Tortora; Alan B Storrow
Journal:  Dis Markers       Date:  2016-03-24       Impact factor: 3.434

8.  Biological variation of ischaemia-modified albumin in healthy subjects.

Authors:  R Govender; J De Greef; R Delport; P J Becker; W J Vermaak
Journal:  Cardiovasc J Afr       Date:  2008 May-Jun       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.